NCT07014878View on ClinicalTrials.gov

A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
PDACCRC (Colorectal Cancer)NSCLCSolid Tumor Malignancies
Interventions
BIOLOGICAL

TCR-T cells

"Dose escalation will follow the standard 3+3 design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially."

Trial Locations (1)

100853

First Medical Center of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Beijing DCTY Biotech Co.,Ltd.

OTHER